Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Cost of Revenue (2024 - 2025)

Autolus Therapeutics (AUTL) has disclosed Cost of Revenue for 2 consecutive years, with $28.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue changed N/A year-over-year to $28.6 million, compared with a TTM value of $82.4 million through Sep 2025, changed N/A, and an annual FY2024 reading of $11.4 million, changed N/A over the prior year.
  • Cost of Revenue was $28.6 million for Q3 2025 at Autolus Therapeutics, up from $24.4 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $28.6 million in Q3 2025 and bottomed at $11.4 million in Q4 2024.